AU2010273974B2 - Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts - Google Patents

Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Download PDF

Info

Publication number
AU2010273974B2
AU2010273974B2 AU2010273974A AU2010273974A AU2010273974B2 AU 2010273974 B2 AU2010273974 B2 AU 2010273974B2 AU 2010273974 A AU2010273974 A AU 2010273974A AU 2010273974 A AU2010273974 A AU 2010273974A AU 2010273974 B2 AU2010273974 B2 AU 2010273974B2
Authority
AU
Australia
Prior art keywords
antibody
protein
cells
template
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010273974A
Other languages
English (en)
Other versions
AU2010273974A8 (en
AU2010273974A1 (en
Inventor
Jay Milton Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of AU2010273974A1 publication Critical patent/AU2010273974A1/en
Publication of AU2010273974A8 publication Critical patent/AU2010273974A8/en
Priority to AU2015243076A priority Critical patent/AU2015243076B2/en
Application granted granted Critical
Publication of AU2010273974B2 publication Critical patent/AU2010273974B2/en
Priority to AU2017203243A priority patent/AU2017203243B2/en
Priority to AU2019203813A priority patent/AU2019203813B2/en
Priority to AU2021203220A priority patent/AU2021203220B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010273974A 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Active AU2010273974B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2015243076A AU2015243076B2 (en) 2009-07-17 2015-10-16 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2017203243A AU2017203243B2 (en) 2009-07-17 2017-05-15 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2019203813A AU2019203813B2 (en) 2009-07-17 2019-05-31 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2021203220A AU2021203220B2 (en) 2009-07-17 2021-05-19 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27116809P 2009-07-17 2009-07-17
US61/271,168 2009-07-17
PCT/US2010/042302 WO2011009058A2 (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015243076A Division AU2015243076B2 (en) 2009-07-17 2015-10-16 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts

Publications (3)

Publication Number Publication Date
AU2010273974A1 AU2010273974A1 (en) 2012-02-09
AU2010273974A8 AU2010273974A8 (en) 2012-02-23
AU2010273974B2 true AU2010273974B2 (en) 2016-01-14

Family

ID=43450243

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2010273974A Active AU2010273974B2 (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
AU2015243076A Active AU2015243076B2 (en) 2009-07-17 2015-10-16 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2017203243A Active AU2017203243B2 (en) 2009-07-17 2017-05-15 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2019203813A Active AU2019203813B2 (en) 2009-07-17 2019-05-31 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2021203220A Active AU2021203220B2 (en) 2009-07-17 2021-05-19 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2015243076A Active AU2015243076B2 (en) 2009-07-17 2015-10-16 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2017203243A Active AU2017203243B2 (en) 2009-07-17 2017-05-15 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2019203813A Active AU2019203813B2 (en) 2009-07-17 2019-05-31 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
AU2021203220A Active AU2021203220B2 (en) 2009-07-17 2021-05-19 Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts

Country Status (18)

Country Link
US (6) US8859467B2 (enExample)
EP (6) EP3406717B1 (enExample)
JP (3) JP6193570B2 (enExample)
KR (5) KR20190017070A (enExample)
CN (2) CN102625848A (enExample)
AU (5) AU2010273974B2 (enExample)
BR (2) BR112012001171B1 (enExample)
CA (2) CA2768247C (enExample)
DK (5) DK2907873T3 (enExample)
ES (3) ES2701931T3 (enExample)
HU (1) HUE029328T2 (enExample)
IN (1) IN2012DN00737A (enExample)
MX (3) MX392642B (enExample)
MY (2) MY160472A (enExample)
PL (2) PL3042957T3 (enExample)
PT (1) PT3042957T (enExample)
SG (3) SG10201700096VA (enExample)
WO (1) WO2011009058A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625848A (zh) 2009-07-17 2012-08-01 生物蛋白有限公司 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
ES2966088T3 (es) * 2010-07-16 2024-04-18 Bioatla Inc Nuevos métodos de evolución de proteínas
AU2015242961B2 (en) * 2010-07-16 2017-03-02 Bioatla, Llc Novel methods of protein evolution
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
WO2013067322A1 (en) * 2011-11-03 2013-05-10 Stc Biologics, Inc. Method for determination of pharmacological properties of recombinant proteins
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂，其制备方法和用途
ES2819865T3 (es) 2014-01-07 2021-04-19 Bioatla Llc Proteínas dirigidas a ortólogos
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CA2947605A1 (en) * 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
WO2016004242A1 (en) * 2014-07-01 2016-01-07 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
EP3186284B1 (en) 2014-08-28 2022-04-06 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US10513699B2 (en) 2014-09-03 2019-12-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
KR102790523B1 (ko) 2015-02-24 2025-04-02 바이오아트라, 인코퍼레이티드 조건부 활성 생체 단백질
KR102725051B1 (ko) * 2015-09-23 2024-11-04 제넨테크, 인크. 항-vegf 항체의 최적화된 변이체들
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
JP7051715B2 (ja) 2016-05-13 2022-04-11 バイオアトラ、エルエルシー 抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
EP3652209A2 (en) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2021005594A (es) 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
EP3955960B1 (en) 2019-04-18 2025-01-15 Bristol-Myers Squibb Company Ipilimumab variants with enhanced specificity for binding at low ph
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
CN111462815B (zh) * 2020-03-27 2023-05-02 上海祥耀生物科技有限责任公司 一种抗体库的构建方法及装置
US11506060B1 (en) * 2021-07-15 2022-11-22 Honeywell International Inc. Radial turbine rotor for gas turbine engine
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4522757A2 (en) 2022-05-13 2025-03-19 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003345A2 (en) * 2003-06-27 2005-01-13 R. Crea & Co. Look-through mutagenesis

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
DE68911648T2 (de) 1988-03-24 1994-06-23 Univ Iowa Res Found Katalytische hybridisierungs-systeme zum nachweis von nukleinsäuresequenzen, die auf deren aktivität als kofaktoren in katalytischen reaktionen basieren in denen eine komplementäre, markierte nukleinsäureprobe gespalten wird.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5677149A (en) 1992-11-24 1997-10-14 G.D. Searle & Co., Interleukin-3 (IL-3) mutant polypeptides and their recombinant production
US20030219752A1 (en) 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US8137906B2 (en) * 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
JP2004532038A (ja) * 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
CA2625619A1 (en) 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
WO2008118476A2 (en) * 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
BRPI0819092A2 (pt) 2007-11-02 2014-10-14 Scripps Research Inst Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
CN102625848A (zh) 2009-07-17 2012-08-01 生物蛋白有限公司 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003345A2 (en) * 2003-06-27 2005-01-13 R. Crea & Co. Look-through mutagenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ho, M. et al "Isolation of anti-CD22 Fv with high affinity by Fv display on human cells" PNAS, vol. 103, pps 9637-9642 *
Miao, H. Z. et al, "Bioengineering of coagulation factor VIII for improved secretion" Blood, 2004, vol. 103, pps 3412-3419 *

Also Published As

Publication number Publication date
EP3636759B1 (en) 2023-10-11
EP3042957B1 (en) 2017-09-13
AU2021203220B2 (en) 2023-05-04
US20180371452A1 (en) 2018-12-27
EP2454376B1 (en) 2015-12-02
DK3636759T3 (da) 2023-10-23
MX392642B (es) 2025-03-19
EP2454376A4 (en) 2013-07-10
DK2907873T3 (en) 2016-06-13
AU2010273974A8 (en) 2012-02-23
EP2907873A1 (en) 2015-08-19
KR20220002712A (ko) 2022-01-06
MX347654B (es) 2017-05-05
AU2017203243B2 (en) 2019-07-11
JP6681131B2 (ja) 2020-04-15
EP3156485A1 (en) 2017-04-19
KR20120069664A (ko) 2012-06-28
IN2012DN00737A (enExample) 2015-06-19
US20240263354A1 (en) 2024-08-08
AU2015243076A1 (en) 2015-11-05
ES2581318T3 (es) 2016-09-05
EP2454376A2 (en) 2012-05-23
CN107090031A (zh) 2017-08-25
EP3156485B1 (en) 2018-09-12
JP2017205110A (ja) 2017-11-24
JP6193570B2 (ja) 2017-09-13
AU2019203813A1 (en) 2019-06-20
AU2015243076B2 (en) 2017-02-23
EP2907873B1 (en) 2016-04-06
EP3042957A1 (en) 2016-07-13
DK3406717T3 (da) 2020-03-16
JP6193913B2 (ja) 2017-09-06
MY160472A (en) 2017-03-15
US10047357B2 (en) 2018-08-14
SG10201505075TA (en) 2015-07-30
DK3042957T3 (en) 2018-01-02
PL3042957T3 (pl) 2018-03-30
PL2907873T3 (pl) 2016-10-31
US11976381B2 (en) 2024-05-07
AU2021203220A1 (en) 2021-06-10
CN102625848A (zh) 2012-08-01
JP2012533307A (ja) 2012-12-27
US20210207129A1 (en) 2021-07-08
AU2010273974A1 (en) 2012-02-09
AU2017203243A1 (en) 2017-06-08
HK1210623A1 (en) 2016-04-29
WO2011009058A2 (en) 2011-01-20
US20120245036A1 (en) 2012-09-27
SG177687A1 (en) 2012-02-28
AU2019203813B2 (en) 2021-03-11
WO2011009058A3 (en) 2011-04-14
US8859467B2 (en) 2014-10-14
MY173037A (en) 2019-12-20
ES2701931T3 (es) 2019-02-26
DK3156485T3 (en) 2019-01-07
PT3042957T (pt) 2017-12-21
BR112012001171A2 (pt) 2017-06-13
SG10201700096VA (en) 2017-02-27
CA3034484A1 (en) 2011-01-20
MX2012000803A (es) 2012-06-01
HUE029328T2 (en) 2017-02-28
EP3636759A1 (en) 2020-04-15
KR20190017070A (ko) 2019-02-19
KR20180010347A (ko) 2018-01-30
BR122015012748A2 (pt) 2020-01-07
US10920216B2 (en) 2021-02-16
EP3406717A1 (en) 2018-11-28
CA2768247C (en) 2019-04-09
BR112012001171B1 (pt) 2021-09-21
CA2768247A1 (en) 2011-01-20
KR20210013294A (ko) 2021-02-03
EP3406717B1 (en) 2019-12-11
US20150024944A1 (en) 2015-01-22
US10106788B2 (en) 2018-10-23
ES2652340T3 (es) 2018-02-01
US20120165201A1 (en) 2012-06-28
JP2015211672A (ja) 2015-11-26
KR101823872B1 (ko) 2018-01-31

Similar Documents

Publication Publication Date Title
AU2021203220B2 (en) Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
US11639365B2 (en) Methods of protein evolution
CA2935577A1 (en) Proteins targeting orthologs
HK40026409A (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1236221A1 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1236221B (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK40000181A (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK40000181B (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1230231A1 (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
HK1230231B (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
HK1210623B (en) Simulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
AU2015242961A1 (en) Novel methods of protein evolution

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 26, NO 4, PAGE(S) 696 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME BIOATIA, LLC, APPLICATION NO. 2010273974, UNDER INID (71) CORRECT THE NAME TO BIOATLA, LLC

FGA Letters patent sealed or granted (standard patent)